Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids

Asian Journal of Pharmaceutical Sciences

Volumn 10, Issue 3, 2015, Pages 194-202

  Yang, Gang ^a   Zhao, Yaping ^b   Feng, Nianping ^a   Zhang, Yongtai ^a   Liu, Ying ^a   Dang, Beilei ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bioavailability; Dissolution; Silymarin; Solid dispersion; Solution enhanced dispersion by supercritical fluids

Indexed keywords

POLYMER; POVIDONE; SILYMARIN;

AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EVAPORATION; GAS CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; RAT; SOLID DISPERSION; SOLID STATE; SUPERCRITICAL FLUID; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

EID: 84937966583     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.12.001     Document Type: Article

References (27)

1. Luper S. A review of plants used in the treatment of liver diseases: part 1. Altern Med Rev 1998, 3:410-421.
2. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006, 124:491-504.
3. Mohamed E.S., Gamal E.S., Tarek M.I. Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis. Eur J Pharmacol 2001, 670:593-600.
4. Freedman N.D., Curto T.M., Morishima C. Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharm Ther 2010, 33:127-137.
5. Dixit N., Baboota S., Kohli K., et al. Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2007, 39:171-179.
6. Giacomelli S., Gallo D., Apollonio P., et al. Silybin and its bioavailable phospholipid complex (IdB1016) potentiate in-vitro and in-vivo activity of cisplatin. Life Sci 2003, 70:1447-1459.
7. Shangguan M.Z., Yi Lu, Qi J.P., et al. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin. J Biomater Appl 2014, 28:887-896.
8. Panapisal V., Charoensri S., Tantituvanont A. Formulation of microemulsion systems for dermal delivery of silymarin. PharmSciTech 2012, 13:389-399.
9. Ahmed S., Mohammed E., Mohammad A. Complement activation assay and in vivo evaluation of silymarin loaded liver targeting liposome. J Life Med 2014, 2:15-24.
10. Sonali D., Tejal S., Vaishali T., et al. Silymarin-solid dispersions: characterization and influence of preparation methods on dissolution. Acta Pharm 2010, 60:427-443.
11. Bobe K., Bobe C.R., Suresh S. Formulation and evalution of solid dispersion of atorvastatin with various carriers. Pharmacie Globale (IJCP) 2011, 1:1-6.
12. Das S.K., Roy S., Kalimuthu Y. Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs. Int J Pharmacol Pharm Technol 2014, 1:2277-3436.
13. Won D.H., Kim M.S., Lee S., et al. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 2005, 301:199-208.
14. Juppo A.M., Boissier C., Khoo C. Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm 2003, 250:385-401.
15. Antonio T., Eva M., Miguel A. Precipitation of tretinoin and acetaminophen with solution enhanced dispersion by supercritical fluids (SEDS). Powder Technol 2012, 217:177-188.
16. Chen Z.Q., Liu Y., Zhao J.H., et al. Improved oral bioavailability of poorly water-soluble indirubin by a supersaturatable self-microemulsifying drug delivery system. Int J Nanomedicine 2012, 7:1115-1125.
17. Kim M.S., Jin S.J., Kim J.S. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2008, 69:454-465.
18. Juan J., Garcia R., Paloma M., et al. Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity. Int J Pharm 2011, 403:23-28.
19. Han H.K., Lee B.J., Lee H.K. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. Int J Pharm 2011, 415:89-94.
20. Guo Y.S., Shalaev E., Scott S. Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions. TRAC-Trend Anal Chem 2013, 49:137-144.
21. Patrick J.M., Alfred C.F.R., David E.N., et al. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly (vinyl pyrrolidone). J Pharm Sci 2009, 99:169-185.
22. Sarode A.L., Sandhu H., Shah N., et al. Hot melt extrusion for amorphous solid dispersions: temperature and moisture activated drug-polymer interactions for enhanced stability. Mol Pharmaceut 2013, 10:3665.
23. Deconinck E., Canfyn M., Sacre P.Y., et al. Evaluation of the residual solvent content of counterfeit tablets and capsules. J Pharmaceut Biomed 2013, 81:80-88.
24. Ke K., Wei X.F., Bao R.Y., et al. Contribution of residual solvent to the nucleation and reinforcement of poly (vinylidene fluoride). Polym Test 2014, 34:78-84.
25. Park Y.J., Xuan J.J., Oh D.H., et al. Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability. Arch Pharm Res 2010, 33:1217-1225.
26. Park J., Cho W., Cha K.H. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int J Pharm 2013, 441:50-55.
27. Li S.M., Liu Y., Liu T., et al. Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm 2011, 411:172-177.